SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the March 2023 quarter is pegged at Rs. 7821.60 millions against Rs. 7919.20 millions recorded during the year-ago period.The Total Profit for the quarter ended March 2023 of Rs. 1314.80 millions grew from Rs.-558.70 millionsOperating Profit saw a handsome growth to 1947.30 millions from 1923.60 millions in the quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 7821.60 7919.20 -1.23 32163.40 32175.10 -0.04 32163.40 32175.10 -0.04
Other Income 279.70 189.40 47.68 1015.20 762.20 33.19 1015.20 762.20 33.19
PBIDT 1947.30 1923.60 1.23 9009.30 8320.50 8.28 9009.30 8320.50 8.28
Interest 6.50 2.70 140.74 18.10 19.90 -9.05 18.10 19.90 -9.05
PBDT 2044.80 2215.90 -7.72 8981.50 8416.40 6.71 8981.50 8416.40 6.71
Depreciation 171.80 153.50 11.92 657.70 681.90 -3.55 657.70 681.90 -3.55
PBT 1873.00 2062.40 -9.18 8323.80 7734.50 7.62 8323.80 7734.50 7.62
TAX 558.20 2621.10 -78.70 2276.80 3968.70 -42.63 2276.80 3968.70 -42.63
Deferred Tax -7.60 24.70 -130.77 -183.70 -105.00 74.95 -183.70 -105.00 74.95
PAT 1314.80 -558.70 -335.33 6047.00 3765.80 60.58 6047.00 3765.80 60.58
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 24.90 24.29 2.50 28.01 25.86 8.32 28.01 25.86 8.32

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×